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SUMMARY ∑ A marked clinical, physiologic, and biochemical connection between osteoporosis
and major depressive disorder (MDD) is described. There are numerous states and diseases associ-
ated with osteoporosis. The aim of the study was to assess the presumed association between
hypercortisolism and osteoporosis. Some recent studies provided evidence for association between
previous history of MDD and marked osteoporosis. In MDD, there are two well documented bio-
chemical abnormalities, hypercortisolism and its resistance to dexamethasone suppression. The present
study included 31 MDD patients (19 male and 12 female), mean age 37±1.3, age range 29-41 years,
and 17 healthy male volunteers, mean age 39±1.6, age range 34-45 years. The levels of free cortisol
in 24-h urine, serum cortisol at 8 a.m. and 5 p.m., and cortisol in dexamethasone suppression test as
well as bone mineral density were measured in all study subjects. The results obtained were analyzed
by use of Spearman’s nonparametric rank correlation, rho=-0.805, with a statistical significance level
of p<0.01 (2-tailed). Study results suggested that patients with a long-term history of depression
may develop a severe form of osteoporosis. Also, a severe form of osteoporosis has been known to
develop in patients with untreated Cushing’s syndrome.
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Introduction
Osteoporosis is the most common bone disease fre-
quently leading to bone fracture. In both men and women,
the incidence of hip fracture rises exponentially with age,
although this increase begins approximately 5 to 10 years
later. Approximately one half of these fractures are verte-
bral fractures, whereas hip fractures and Colles’ fractures
account for one fourth each. Osteoporosis is the leading
cause of morbidity and mortality in elderly people.
The disorders that cause osteoporosis are similar in
men and women and include estrogen deficiency, prima-
rily in postmenopausal women, hyperparathyroidism,
hyperthyroidism, hypogonadism in men, glucocorticoid
therapy, genetic factors, cigarette smoking and alcohol
intake, lower calcium intake, decreases in physical activ-
ity and muscle strength, gastrointestinal disease, vitamin
D deficiency, anticonvulsant therapy, and stress factors
with depression. The usual clinical manifestations of os-
teoporosis are low trauma fractures and radiographic
osteopenia detected by chance or during evaluation for
musculoskeletal pain, usually back pain.
Measurements of bone mineral density are usually
recommended, and if bone mineral density is lower than
expected for age and no cause is apparent, further studies
are indicated, including measurements of serum testoster-
one, thyrotropin, calcium, alkaline phosphatase, 25-
hydroxyvitamin D, parathyroid hormone, urinary calcium
and creatinine, complete blood count, serum and urine
protein electrophoresis, and iliac crest bone biopsy.
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If the cause of osteoporosis can be identified, the po-
tential offending agents should be eliminated whenever
possible. As a rule, patients should receive adequate calcium
(1000 mg/day) and vitamin D (800 IU/day) supplementa-
tion. A weight-bearing exercise regimen may also be ben-
eficial, given the association of reduced physical activity.
Major depressive disorder (MDD) is a syndrome of
persistingly sad, dysphoric mood accompanied by sleep
and appetite disturbances, and inability to experience plea-
sure. The diagnosis of MDD is made when the patient
meets the DSM-IV criteria. At least five of the following
symptoms must be present during a 2-week period and
show change from the previous condition: depressed mood
most of the day, nearly every day; anhedonia and dimin-
ished interest in general; significant weight change not
related to diet; sleep disturbances; psychomotor agitation
or retardation, loss of energy; feeling of worthlessness or
inappropriate guilt; concentration disturbances; recurrent
thoughts of death; and suicidal ideas or specific plan for
committing suicide.
In MDD, there are two well documented biochemi-
cal abnormalities: hypercortisolism and its resistance to
dexamethasone suppression. Activation of the pituitary-
adrenal axis is fairly specific for depression among other
conditions of primary affective disorders, and could be
observed in as many as 40%-60% of patients in some se-
ries. These findings have eventually led to the routine use
of dexamethasone suppression test (DST) as a biological
tool for both diagnostic and follow-up purposes in such
patients. Psychotherapy associated with antidepressants
(serotonin reuptake inhibitors, tricyclic antidepressants,
anxiolytics, and mood stabilizers) have been found to
improve impulsive behavior.
Subjects and Methods
The study included 31 patients with MDD, 19 male
and 12 female, mean age 37±1.3, age range 29-41 years,
and 17 healthy male volunteers, mean age 39±1.6, age
range 34-45 years. In order to determine the hypercor-
tisolic state, it was essential to develop a tool to assess the
cortisolic state and to identify, for a given individual,
whether it was inappropriately high. An ideal parameter
would be the one that shows no overlapping between
normal subjects, including the obese, and patients with
hypercortisolic state of whatever etiology.
Plasma cortisol is measured by the competitive protein
binding assay, or recently by more specific immunoassays.
Plasma free cortisol is the best indicator of the cortisolic
state. It is a biologically relevant and highly sensitive pa-
rameter.
Serum cortisol level was determined by standard ra-
dioimmunoassay (RIA) using 125 J labeled hormone, since
it binds non-labeled serum cortisol to specific antibodies
according to their concentration in the radioactive mix-
ture. Venous blood samples of 5 ml were obtained in the
morning (8 a.m.) and in the afternoon (5 p.m.) after 30-
min bed rest. According to cyclic hypothalamic secretion
of CRF, the rate of cortisol secretion in a healthy person
is higher in the early morning and lower in the early
evening. Falsely elevated values can be found in pregnancy
and in women taking oral contraceptives, whereas no nor-
mal diurnal variations are found in stress patients. At our
laboratory, normal values are 138-800 nmol/L at 8 a.m.,
and 50%∑70% of the morning values at 5 p.m.
Free 24-hour urinary cortisol excretion is an almost
ideal marker of the cortisolic state. Urinary cortisol is
measured by the competitive protein binding assay after
extraction, or by immunoassay. Study subjects were in-
structed to collect urine samples after first morning void
until the next morning, including first void on the next day.
Normal values are 150-750 mmol/24 h. Since it correlates
with the levels of plasma free cortisol, urinary cortisol
excretion has several invaluable properties: it is biologically
relevant, being a reflection of how much biologically ac-
tive, free cortisol has been circulating over the last 24-h
period; it is a highly sensitive marker. It is not altered in
obese subjects, estrogen-treated females, or by drugs or
conditions that modify the metabolism of cortisol.
DST included oral administration of two 0.5-mg dex-
amethasone tablets at 11 p.m., followed by venous blood
sampling at 8 a.m. and 5 p.m. on the next day. In DST,
synthetic steroid analogs have been chosen for their high
glucocorticoid potency; they would suppress the adreno-
corticotropic hormone (ACTH) given in minute amounts
as compared with the daily amount or normally secreted
cortisol. It has been established that 0.5 mg of dexametha-
sone given every 6 hours in eight doses (2 mg/day) induce
almost complete suppression. In the present study, serum
cortisol level, 24-h urinary free cortisol and DST were
determined in both patients and control subjects.
Results
Results of the study showed the mean basal 24-h uri-
nary cortisol in MDD patients to be 1067±61.8 nmol/l.
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Serum cortisol at 8 a.m. and 5 p.m. was 618±43.2 and
347±34.2 nmol/l, respectively. Cortisol in DST was
165±36.8 nmol/l. Plasma levels of cortisol in MDD pa-
tients were just above the normal range. MDD patients
also showed deficient cortisol suppression in DST. These
results indicated that, although showing an increase in the
urinary level of cortisol, MDD patients had some circa-
dian rhythm of cortisol preserved (Figs. 1 and 2).
The study revealed a significant correlation between
years of therapy and grade of osteoporosis in MDD pa-
tients (Fig. 4). So, a patient treated with antidepressant
therapy for a longer period of time was more likely to
develop osteoporosis. MDD patients had statistically sig-
nificantly higher levels of cortisol in 24-h urine.
Statistical analysis was performed by use of nonpara-
metric rank correlation, where Spearman’s rho was -0.805,
with correlation significance at a level of p<0.01 (Tables
1 and 2).















Fig. 2. Plasma cortisol in MDD patients and healthy volunteers at



















Fig. 3. Urinary free cortisol, plasma cortisol at 8 a.m. and 5 p.m.,



























Fig. 4. Correlation between years of therapy and T score in patients
with MDD and osteoporosis.
Discussion
The hypothalamo ∑ pituitary ∑ adrenal (HPA) axis is
a very complex control system playing an important role
primarily in stress reaction. Glucocorticoids are secreted
in response to stressful conditions, and have an important
task to block the function of stress mediators that have
previously been brought to liberation. In other words, glu-
cocorticoids suppress the autonomic (vegetative), behav-
ioral, endocrine, and immune responses to stressful stimuli
in a time-dependent way.
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HPA axis is under control of various neurotransmit-
ter systems. Some authors consider that serotonin, acetyl-
choline and histamine show stimulatory, and noradrena-
line and GABA inhibitory effects. During stress, HPA
axis acts differently according to the actual task, i.e. ‘to
fight or to flight’. Immobilization reflex (withdrawal re-
action from fight) with motility inhibition and conserva-
tion of energy is under control of hippocampus and adre-
nal cortex activation by ACTH and corticosterone in-
crease.
Biological abnormality is frequently observed in pa-
tients with MDD, presumably secondary to ACTH hy-
persecretion. The ability of the glucocorticoid negative
feedback system to limit the production of cortisol dur-
ing stress can be impaired by chronic emotional or physi-
cal stress, and by old age. Glucocorticoid-induced hippoc-
ampal neuron damage and deficient transmission of supra-
hypothalamic negative feedback have been proposed as a
major mechanism mediating this phenomenon. Indeed, in
patients with depression, the 24-h urinary free cortisol
excretion increases with age, while studies of HPA axis in
aging population that included persons with chronic emo-
tional or physical diseases have shown progressive eleva-
tions of evening plasma cortisol concentrations with age.
In MDD, hypercortisolism does not give rise to the
usual physical stigmata of hypercortisolic state (moon face,
buffalo hump, hypertension, easy bruising, purple striae) and
reverts to normal when the depression remits, either spon-
taneously or due to antidepressants or other therapy. Some
studies have shown that urinary cortisol excretion in depres-
sion never exceeds 3-fold upper limit of the normal. The
circadian pattern of plasma cortisol is less disrupted.
Activation of pituitary ∑ adrenal axis is fairly specific
for depression among other conditions of primary affec-
tive disorders. So, these findings have eventually led to the
routine use of DST as a biological tool for both the diag-
nosis and follow-up of these patients. Studies focused on
the pathophysiology of the HPA axis dysfunction in
MDD patients have been reported. Four hypotheses have
been proposed to explain why nonsuppression occurs.
These include: 1) increased metabolism of dexamethasone
in patients with MDD, which results in less dexametha-
sone available to suppress the production of ACTH in the
pituitary gland; 2) decreased sensitivity of the pituitary
glucocorticoid receptors to dexamethasone, resulting in
less ACTH suppression and cortisol elevation; 3) hyper-
responsitivity of the adrenal gland to ACTH stimulation,
resulting in continued cortisol secretion despite moderate
to significant ACTH suppression with dexamethasone;
and 4) increased central drive of the pituitary from the
hypothalamic-limbic structures, which overrides the ac-
tion of dexamethasone. The more so, a combination of the
hypotheses should by no means be neglected.
The use of anticortisol drugs has already been demon-
strated to be beneficial in depression. There must have
been misinterpretation of cortisol results. If serum corti-
sol levels were normal at 8 a.m. and 5 p.m., they used to
be considered normal, without realizing that changes,
sometimes at the immunosuppressive level, might occur
during the 24-h circadian rhythm.
Table 1. Correlation between years of therapy and T score in MDD
patients
Correlation Year T score
of therapy
Year of therapy Pearson’s
correlation 1,000 -,787*




Sig. (2-tailed) ,000 ,
n 37 37
*correlation significant at a level of 0.01 (2-tailed)
Table 2. Correlation between years of therapy and T score in MDD
patients




Correlation coefficient 1,000 -,805
Sig. (2-tailed) , ,000
n 37 37
T score
Correlation coefficient -,805* 1,000
Sig. (2-tailed) ,000 ,
n 37 37
*correlation significant at a level of 0.01 (2-tailed)
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Saæetak
MOÆE LI DUGOTRAJNA VELIKA DEPRESIJA IZAZVATI OSTEOPOROZU?
M. Vrkljan, B. Vizner, M. BekiÊ, V. Thaller i Z. Sonicki
Opisana je kliniËka, fizioloπka i biokemijska povezanost osteoporoze i velike depresije. U oba stanja dolazi do hiperaktivnosti
osi HPA, sustava LC/NE, te poviπenog luËenja CRH, kortizola i katekolamina. Mnoga stanja i bolesti povezane su s
osteoporozom, ukljuËujuÊi hiperkorticizam. Novija istraæivanja povezuju raniju povijest velike depresije s osteoporozom. U
velikoj depresiji zabiljeæene su dvije biokemijske abnormalnosti: hiperkorticizam i rezistencija na supresiju deksametazonom.
U naπe je istraæivanje bio ukljuËen 31 bolesnik s velikom depresijom (19 muπkaraca i 12 æena) prosjeËne dobi od 37±1,3 godine,
te 17 muπkih dobrovoljaca u dobi od 34 do 45 godina, prosjeËne dobi od 39±1,6 godina. U svih je bolesnika odreivana razina
kortizola u 24-satnoj mokraÊi, serumski kortizol, kortizol u testu supresije deksametazonom, a gustoÊa kostiju je odreivana
denzitometrijski. Bila je to skupina mlaih muπkaraca i æena s odræanim menstruacijskim ciklusom, u poËetku bez osteoporoze,
ali godinama pod antidepresivnom terapijom. Analiza rezultata pokazala je poviπene vrijednosti kortizola, te pojavu osteoporoze
razvoj koje je bio posljedica poviπene razine kortizola. U analizi rezultata primijenjena je neparametrijska korelacija rangova,
priËem je Spearmanov rho bio -0,805 uz statistiËku znaËajnost od p<0,01. Na temelju rezultata ispitivanja zakljuËeno je da
bolesnici lijeËeni zbog depresije imaju poviπenu razinu kortizola u 24-satnoj mokraÊi. Bolesnici koji su duæe bolovali od
depresije imali su jaËe izraæenu osteoporozu. Kortizol vjerojatno ima znaËajnu ulogu u nastanku osteoporoze u bolesnika s
depresijom, a poznato je da se u bolesnika s nelijeËenim Cushingovim sindromom takoer razvija jak oblik osteoporoze.
KljuËne rijeËi: Osteoporoza, etiologija; Depresija, fiziopatologija; Kost i koπtani metabolizam
